Condition: Acute Myeloid Leukemia (AML) · Sponsor: Aptevo Therapeutics
A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
This description comes directly from the study's public registry record.
Caroline Taromino · 7735749572 · tarominoC@apvo.com
Always discuss trial participation with your own doctor first.
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| University of Kansas | Fairway, Kansas, United States | Recruiting |
| Gabrail Cancer Center | Canton, Ohio, United States | Recruiting |
| Oncology Hematology Care | Cincinnati, Ohio, United States | Recruiting |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06634394